Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06660290 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes
A Phase 3 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 55
- Enrollment target
NCT06660290 is a Phase 3 study that has completed, run by Alcon Research. The registered enrollment target is 55 participants.
The verdict
NCT06660290, a Phase 3 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 55 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the percentage of ocular adverse events reported in subjects with dry eye disease (DED) between the intervention arm (0.003% AR-15512) and control arm (REFRESH® Classic).
Interventions
- DRUG Artificial tears
- DRUG 0.003% AR-15512 ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2025-01-15 |
| Est. Completion | 2025-02-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06660290
The ClinicalTrials.gov registry entry for NCT06660290 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Artificial tears is the first listed.
NCT06660290 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06660290 about?
NCT06660290 is a clinical study titled "A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes". The purpose of this study is to evaluate the percentage of ocular adverse events reported in subjects with dry eye disease (DED) between the intervention arm (0.003% AR-15512) and control arm (REFRESH® Classic).
What is the current status of trial NCT06660290?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 55 participants. The study started on 2025-01-15. Estimated completion is 2025-02-06.
What interventions are being tested in trial NCT06660290?
The interventions under investigation include: Artificial tears (DRUG), 0.003% AR-15512 ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT06660290?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.